Seeking Alpha

ViroPharma (VPHM +3.4%) trades higher after releasing its 2013 outlook this morning. The company...

ViroPharma (VPHM +3.4%) trades higher after releasing its 2013 outlook this morning. The company says it expects net product sales to be between $450M to $475M. Analysts are looking for around $467M. The numbers are encouraging, because Cinryze has become key to the drug developer's future as the it's former blockbuster antibiotic Vancocin is expected to see sales hurt by the potential entry of generic rivals going forward.
Comments (1)
  • cgm
    , contributor
    Comments (144) | Send Message
     
    The management here has played their drug development well. They have gone from a "one-trick pony" to a firm that brings additional income sources to market in thime to more than offset the effects of generic competition. The stock has acted well as a result. One very pleased stockholder here.
    7 Jan 2013, 01:04 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|